How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/chronic-non-neuropathic-gaucher-s-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Chronic non-neuropathic Gaucher's disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chronic non-neuropathic Gaucher's disease (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chronic non-neuropathic Gaucher's disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	First approval
Vpriv	VELAGLUCERASE ALFA	Shire Human Genetic	Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC]	2010-01-01
Ceredase	ALGLUCERASE	Sanofi	Hydrolytic Lysosomal Glucocerebroside-specific Enzyme	1991-01-01
glucocerebrosidase	glucocerebrosidase	National Center for Research Resources (NCRR)

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

National Center for Research Resources (NCRR) · 1 drug in Chronic non-neuropathic Gaucher's disease
Sanofi · 1 drug in Chronic non-neuropathic Gaucher's disease
Shire Human Genetic · 1 drug in Chronic non-neuropathic Gaucher's disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chronic non-neuropathic Gaucher's disease:

Cite this brief

Drug Landscape (2026). Chronic non-neuropathic Gaucher's disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-non-neuropathic-gaucher-s-disease. Accessed 2026-06-10.

Chronic non-neuropathic Gaucher's disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing